A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2024 № 4

L.S. Butaev1,2, Yu.A. Oleynik1, M.P. Bulusov1, A.Yu. Subora1, V.A. Zherebtsova1,
A.M. Sukhareva1, E.S. Urnova1, D.G. Kisilichina1, V.V. Ptushkin1, T.A. Astrelina2, A.S. Samoilov2

Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell
(Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center)

1S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russiа

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center  of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Astrelina Tatyana Alekseevna: t_astrelina@mail.ru

Abstract
Patients with relapsed or refractory (r/r) DLBCL, primary mediastinal B-cell lymphoma and early relapse (up to 2 years) FL have a poor prognosis and short overall survival. Standard second-line chemotherapy for patients under 60-65 years old with r/r DLBCL includes intensive chemotherapy courses with platinum drugs and autologous stem cell transplantation (ASCT). It is known that response to therapy is achieved only in half of patients against the background of standard chemotherapy. Addition of new targeted drugs can improve treatment outcomes. This paper presents the first results of adding Venetoclax to chemotherapy in patients with r/r aggressive B-cell lymphomas.

Keywords: venetoclax, relapsed or refractory B-cell lymphomas, survival, complete remission

For citation: Butaev LS, Oleynik YuA, Bulusov MP, Subora AYu, Zherebtsova VA, Sukhareva AM, Urnova ES, Kisilichina DG, Ptushkin VV, Astrelina TA, Samoilov AS. Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center). A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2024.4:25-33. (In Russian) DOI: 10.33266/2782-6430-2024-4-25-33

 

REFERENCES

  1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127:2375-2390. DOI: https://doi.org/10.1182/blood-2016-01-643569
  2. Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute Sponsored Study of Classification of Non-Hodgkin’s Lymphomas: Summary and Description of Working Formulation for Clinical Usage. Cancer. 1982;49:2112–2135.
  3. Schuster S.J., Bishop M.R., Tam C.S., Waller E.K., Borchmann P., McGuirk J.P., et al. Tisagen Lecleu Cel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019;380:45-66. DOI: http://doi/10.1056/NEJMoa1804980
  4. Locke F.L., Ghobadi A., Jacobson C.A., Miklos D.B., Lekakis L.J., Oluwole O.O., et al. Long-term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (Zuma-1): a Single-Arm, Multicentre, Phase 1-2 Trial. Lancet Oncol. 2019; 20:31-42. DOI: http://doi.org/10.1016/S1470- 2045(18)30864-7
  5. Hirayama A.V., Gauthier J., Hay K.A., Voutsinas J.M., Wu Q., Pender B.S., et al. High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T Cell Immunotherapy. Blood. 2019;134:636-40. DOI: https://doi.org/10.1182/blood.2019000905
  6. Tavakkoli M., Barta S.K. 2024 Update: Advances in the Risk Stratification and Management of Large B-cell Lymphoma. Am. J. Hematol. 2023;98;11:1791‐1805. DOI:10.1002/ajh.27075
  7. Roberts A.W., Davids M.S., Pagel J.M., Kahl B.S., Purvada S.D., Gerecitano J.F., Kipps T.J., Anderson M.A., Brown J.R., Gressick L., Wong S., Dunbar M., Zhu M., Desai M.B., Cerri E., Enschede S.H., Humerickhouse R.A., Wierda W.G., Seymour J.F. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016;374:311-22. https://doi/10.1056/NEJMoa1513257
  8. Seymour J.F., Kipps T.J., Eichhorst B., Hillmen P., D’Rozario J., Assouline S., Owen C., Gerecitano J., Robak T. De la Serna J., Jaeger U., Cartron G., Montillo M., Humerickhouse R., Punnoose E.A., Li Y., Boyer M., Humphrey K., Mobasher M., Kater A.P. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2018;378:1107-20. https://doi.org/10.1056/NEJMoa1713976
  9. DiNardo C.D., Pratz K.W., Letai A., Jonas B.A., Wei A., Thirman M., et al. Safety and Preliminary Efficacy of Venetoclax with Decitabine or Azacitidine in Elderly Patients with Previously Untreated Acute Myeloid Leukaemia: a non-Randomised, Open-Label, Phase 1 B Study. Lancet Oncol. 2018;19:216-28. DOI: https://doi.org/10.1016/S1470-2045(18)30010-X
  10. Davids M.S., Roberts A.W., Seymour J.F., Pagel J.M., Kahl B.S., Wierda W.G., Puvvada S., Kipps T.J., Anderson M.A., Salem A.H., Dunbar M., Zhu M., Peale F., Ross J.A., Gressick L., Desai M., Kim S.Y., Verdugo M., Humerickhouse R.A., Gordon G.B., Gerecitano J.F. Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. J. Clin. Oncol. 2017;35:826-833. https://doi.org/10.1200/JCO.2016.70.4320
  11. Fink S.L., Cookson B.T. Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells. Infect. Immun. 2005;73:1907–1916.
  12. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics. Br. J. Cancer. 1972;26:239–257.
  13. Cory S., Adams J.M. The Bcl2 Family: Regulators of the Cellular Life-or-Death Switch. Nat Rev Cancer. 2002;2:647–656.
  14. Hanahan D., Weinberg R.A. The Hallmarks of Cancer. Cell. 2000;100:57–70.
  15. Huang D.C.S., Hahne M., Schroeter M., et al. Activation of Fas by FasL Induces Apoptosis by a Mechanism that Cannot be Blocked by Bcl-2 or Bcl-xL. Proc. Natl. Acad Sci USA. 1999;96:14871–14876.
  16. Strasser A., Harris AW., Huang DC., Krammer PH., Cory S. Bcl-2 and Fas/APO-1 Regulate Distinct Pathways to Lymphocyte Apoptosis. EMBO J. 1995;14:6136–614.
  17. Guicciardi M.E., Gores G.J. Life and Death by Death Receptors. FASEB J. 2009;23:1625–1637.
  18. Chen L., Willis S.N., Wei A., et al. Differential Targeting of Prosurvival Bcl-2 Proteins by their BH3-only Ligands Allows Complementary Apoptotic Function. Mol Cell. 2005;17:393–403.
  19. Chittenden T. BH3 Domains: Intracellular Death-Ligands Critical for Initiating Apoptosis. Cancer Cell. 2002;2:165–166.
  20. Czabotar P.E., Lessene G., Strasser A., Adams J.M. Control of Apoptosis by the BCL-2 Protein Family: Implications for Physiology and Therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
  21. Huang D.C., Strasser A. BH3-Only Proteins-Essential Initiators of Apoptotic Cell Death. Cell. 2000;103:839–842.
  22. Willis S.N., Chen L., Dewson G., et al. Proapoptotic Bak is Sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, Until Displaced by BH3-Only Proteins. Genes Dev. 2005;19:1294–1305.
  23. Willis S.N., Fletcher J.I., Kaufmann T., et al. Apoptosis Initiated when BH3 Ligands Engage Multiple Bcl-2 Homologs, not Bax or Bak. Science. 2007;315:856–859.
  24. Gazzaniga P., Gradilone A., Vercillo R., et al. Bcl-2/Bax mRNA Expression Ratio as Prognostic Factor in Low-Grade Urinary Bladder Cancer. Int J Cancer. 1996;69:100–104.
  25. Jiang S-X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 Oncogene Protein is Prevalent in Small Cell Lung Carcinomas. J Pathol. 1995;177:135–138.
  26. Joensuu H., Pylkkänen L., Toikkanen S. Bcl-2 Protein Expression and Long-Term Survival in Breast Cancer. Am J Pathol. 1994;145:1191–1198.
  27. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent Deletions and Down-Regulation of Micro-RNA Genes miR15 and miR16 at 13q14 in Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA. 2002;99:15524–15529.
  28. Monni O., Joensuu H., Franssila K., Knuutila S. Dna Copy Number Changes in Diffuse Large B-Cell Lymphoma–Comparative Genomic Hybridization Study. Blood. 1996;87:5269–5278.
  29. Pekarsky Y., Croce C.M. Role of miR-15/16 in CLL. Cell Death Differ. 2015;22:6–11.
  30. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the T (14;18) Chromosome Translocation. Science. 1984;226:1097–1099.
  31. Edelmann J., Holzmann K., Miller F., et al. High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations. Blood. 2012;120:4783–4794.
  32. Döhner H., Stilgenbauer S., Benner A., et al. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Med. 2000;343:1910–1916.
  33. Toshiyuki M., Reed J.C. Tumor Suppressor p53 is a Direct Transcriptional Activator of the Human Bax Gene. Cell. 1995;80:293–299.
  34. Nakano K., Vousden K.H. PUMA, a Novel Proapoptotic Gene, is Induced by p53. Mol Cell. 2001;7:683–694.
  35. Yu J., Wang Z., Kinzler K.W., Vogelstein B., Zhang L. PUMA Mediates the Apoptotic Response to p53 in Colorectal Cancer Cells. Proc Natl Acad Sci USA. 2003;100:1931–1936.
  36. Petros A.M., Gunasekera A., Xu N., Olejniczak E.T., Fesik S.W. Defining the p53 DNA-Binding Domain/Bcl-x (L)-Binding Interface Using NMR. FEBS Lett. 2004;559:171–174.
  37. Zilfou J.T., Lowe S.W. Tumor Suppressive Functions of p53. Cold Spring Harb Perspect Biol. 2009;1:001883.
  38. Dansen T.B., Whitfield J., Rostker F., Brown-Swigart L., Evan G.I. Specific Requirement for Bax, not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo. J Biol Chem. 2006;281:10890–10895.
  39. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a Suppressor of Myc-Induced Mouse B Cell Leukemia. Proc Natl Acad Sci USA. 2004;101:6164–6169.
  40. Mihalyova J., et al. Experimental Hematology. 2018;61:10–25.
  41. Nikiforov M.A., Riblett M., Tang W.H., et al. Tumor Cell-Selective Regulation of NOXA by c-MYC in Response to Proteasome Inhibition. Proc Natl Acad Sci USA. 2007;104:19488–19493.
  42. Hoffman B., Liebermann D.A. Apoptotic Signaling by c-MYC. Oncogene. 2008;27:6462-6472.
  43. Meyer N., Kim S.S., Penn L.Z. The Oscar-Worthy Role of Myc in Apoptosis. Semin Cancer Biol. 2006;16:275–287.
  44. Nieminen A.I., Partanen J.I., Klefstrom J. C-Myc Blazing a Trail of Death: Coupling of the Mitochondrial and Death Receptor Apoptosis Pathways by c-Myc. Cell Cycle. 2007;6:2464–2472.
  45. Nilsson J.A., Cleveland J.L. Myc Pathways Provoking Cell Suicide and Cancer. Oncogene. 2003;22:9007–9021.
  46. Kipps T.J., Eradat H., Grosicki S., et al. A Phase 2 Study of the BH3 Mimetic BCL2 Inhibitor Navitoclax (ABT-263) with or Without Rituximab, in Previously Untreated B-cell Chronic Lymphocytic Leukemia. Leuk Lymphoma. 2015;56:2826–2833.
  47. Nguyen M., Marcellus R.C., Roulston A., et al. Small Molecule Obatoclax (GX15-070) Antagonizes MCL-1 and Overcomes MCL-1-Mediated Resistance to Apoptosis. Proc Natl Acad Sci USA. 2007;104:19512–19517.
  48. Nguyen M., Cencic R., Ertel F., et al. Obatoclax is a Direct and Potent Antagonist of Membrane-Restricted Mcl-1 and is Synthetic Lethal with Treatment that Induces Bim. BMC Cancer. 2015;15:568.
  49. Sun Y., Wu J., Aboukameel A., et al. Apogossypolone, a Nonpeptidic Small Molecule Inhibitor Targeting Bcl-2 Family Proteins, Effectively Inhibits Growth of Diffuse Large Cell Lymphoma Cells In Vitro and In Vivo. Cancer Biol Ther. 2008;7:1418–1426.
  50. Roberts A.W., Seymour J.F., Brown J.R., et al. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients with Relapsed or Refractory Disease. J Clin Oncol. 2012;30:488–496.
  51. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res. 2008;68:3421–3428.
  52. Wilson W.H., O’Connor O.A., Czuczman M.S., et al. Navitoclax, a Targeted High-Affinity Inhibitor of BCL-2, in Lymphoid Malignancies: a Phase 1 Dose-Escalation Study of Safety, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity. Lancet Oncol. 2010;11:1149–1159.
  53. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., et al. ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets. Nat Med. 2013 Feb;19;2:202–8.
  54. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of Apoptosis Sensitivity and Resistance to the BH3 Mimetic ABT-737 in Acute Myeloid Leukemia. Cancer Cell. 2006 Nov;10;5:375–88.
  55. Salem A.H., Agarwal S.K., Dunbar M., Enschede S.L.H, Humerickhouse R.A., Wong S.L. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. J Clin Pharmacol. 2017 Apr;57;4:484–92.
  56. Salem A.H., Agarwal S.K., Dunbar M., Nuthalapati S., Chien D., Freise K.J., et al. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. J Clin Pharmacol. 2016 Nov;56;11:1355–61.
  57. Agarwal S.K., Hu B., Chien D., Wong S.L., Salem A.H. Evaluation of Rifampin’s Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study. J Clin Pharmacol. 2016 Nov;56;11:1335–43.
  58. Freise K.J., Jones A.K., Eckert D., Mensing S., Wong S.L., Humerickhouse R.A., et al. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Pharmacokinet. 2016 Sep 15;56:515-523.
  59. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO Classification of Lymphoid Neoplasms and Beyond: Evolving Concepts and Practical Applications. Blood. 2011 May 12;117;19:5019–32.
  60. Kramer M.H., Hermans J., Wijburg E., Philippo K., Geelen E., van Krieken J.H., et al. Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-cell Lymphoma. Blood. 1998 Nov 1;92;9:3152–62.
  61. Sethi A., Tandon A., Mishra H., Singh I. Diffuse Large B-cell Lymphoma: An Immunohistochemical Approach to Diagnosis. J Oral Maxillofac Pathol. 2019 May-Aug; 23;2:284-288 DOI: 10.4103/jomfp.JOMFP_294_18
  62. Saito M., Gao J., Basso K., Kitagawa Y., Smith P.M., Bhagat G., et al. A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. Cancer Cell. 2007 Sep;12;3:280–92.
  63. Aukema S.M., Siebert R., Schuuring E., Imhoff G.W. van, Kluin-Nelemans H.C., Boerma E-J., et al. Double-Hit B-cell Lymphomas. Blood. 2011 Feb 24;117;8:2319–31.
  64. Imhoff G.W. van, McMillan A., Matasar M.J., et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928). Blood 2014;124;21:630. doi: https://doi.org/10.1182/blood.V124.21.630.630
  65. Morschhauser F., et al. A Phase 2 study of Venetoclax Plus R-CHOP as First-Line Treatment for Patients with Diffuse Large B-cell Lymphoma. Blood. 137;5;2021:600-609. DOI: 10.1182/blood.202000657
  66. Rutherford S.C., Abramson J.S., Bartlett N.L., et al. Venetoclax with Dose-Adjusted EPOCH-R as Initial Therapy for Patients with Aggressive B-cell Lymphoma: a Single-Arm, Multicentre, Phase 1 Study. Lancet Haematol. 2021;8;11:e818-e827
  67. Abramson J.S., Ruppert A.S., Giri S., et al. Randomized Phase II/III Study of DA-EPOCH-R +/ Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. Blood. 2021;138;1:523.
  68. Davids M.S., Roberts A.W., Seymour J.F., Pagel J.M., Kahl B.S., Wierda W.G., et al. Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Jan 17; JCO.2016.70.4320
  69. Hughes M.E., Landsburg D.J., Rubin D.J., Schuster S.J., Svoboda J., Gerson J.N., et al. Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma with Venetoclax: a Single-Center Evaluation of Off-Label use. Clin Lymphoma Myeloma Leukemia. 2019;19;12:791–8. DOI: 10.1016/j.clml.2019.09.612
  70. Wang L., Li L.R., Young K.H. New agents and regimens for diffuse large B Cell Lymphoma. J Hematol Oncol. 2020;13;1:175. Published 2020 Dec 14. DOI:10.1186/s13045-020-01011-z
  71. Caimi P.F., Cashen A., Gallogly M., Winter A., Boughan K., Ghobadi A., Jagadeesh, D., Cooper B., Mehta-Shah N., Dean R., Metheny L., Pohlman B., Bartlett N.L., de Lima M., Kahl B.S., Hill B.T. Venetoclax Combined with R-ICE (VICER) for Second line Treatment of Diffuse Large B Cell Lymphoma Refractory or Relapsed after Initial Chemoimmunotherapy. Hematological Oncology. 2023;41:436-437. https://doi.org/10.1002/hon.3164_321

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 13.05.2024. Accepted for publication: 11.06.2024

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top